FDA warned DrMedHealth over false website claims that compounded semaglutide and tirzepatide have the same active ingredient as Ozempic and Mounjaro.
What happened
FDA reviewed DrMedHealth’s website in March 2026 and found it offered compounded semaglutide and tirzepatide products. FDA said the site claimed these products had the “same active ingredient as Ozempic®” and “same active ingredient as Mounjaro®,” which FDA treats as false or misleading because compounded drugs are not FDA-approved.
What FDA found
The website claimed compounded semaglutide and tirzepatide had the same active ingredient as Ozempic and Mounjaro, implying FDA approval or evaluation that the compounded products do not have.
FD&C Act § 502(a), 21 U.S.C. § 352(a)FDA says the advertising or promotion of the compounded drugs was false or misleading.
FD&C Act § 502(bb), 21 U.S.C. § 352(bb)Selling or shipping these misbranded drugs in interstate commerce is prohibited.
FD&C Act § 301(a), 21 U.S.C. § 331(a)
What FDA wants
FDA tells DrMedHealth to respond in writing to CDER’s Office of Compounding Quality and Compliance within 15 business days, explaining corrective steps and preventing recurrence, including identifying the entities that produce the drugs and providing labeling samples.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounding pharmacies whose products are advertised online
- brands and websites that compare compounded drugs to FDA-approved products
This is a summary. Read the original letter on fda.gov.